STOCK TITAN

Iperionx SEC Filings

IPX NASDAQ

Welcome to our dedicated page for Iperionx SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

IperionX Limited filings document foreign private issuer reports, operating updates, governance actions, and market disclosures for a Nasdaq and ASX-listed titanium technology company. Form 6-K exhibits include quarterly reports on titanium powder production and component manufacturing, shareholder letters, investor presentations, meeting materials, ASX correspondence, and notices of company secretary and registered-office changes.

The filings describe the company’s HAMR™ and HSPT™ technologies, Virginia Titanium Manufacturing Campus, Titan critical minerals project, U.S. Department of War grant programs, reimbursement mechanics, equipment procurement treatment, and customer-related manufacturing activity. Governance and ownership disclosures cover shareholder meeting results, equity incentive approvals, director and officer ownership changes, and communications between the company and ASX.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

IperionX Limited (IPX) filed its FY2025 Form 20‑F, highlighting continued scale-up of U.S. titanium manufacturing alongside operating losses. The company reported a net loss of $35.3 million for fiscal 2025 versus $21.8 million in 2024, with cash reserves of $54.8 million and net assets of $92.4 million at June 30, 2025.

IperionX has commissioned commercial operations at its Virginia Titanium Manufacturing Campus at 125 metric tons per year, and outlined plans to scale to 1,400 metric tons per year in 2027. The company also notes the U.S. government currently holds title to certain Titanium Production Facility assets acquired with federal funds, with a possible transfer after January 30, 2027 subject to conditions.

Shares outstanding were 319,927,854 ordinary shares as of June 30, 2025. Management states prior internal control material weaknesses were remediated as of June 30, 2025. The filing reiterates risks around financing needs, scaling production, market demand for titanium, permitting and compliance, and reliance on government-supported assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
annual report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.79%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.36%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.28%
Tags
current report
-
Rhea-AI Summary

IperionX Limited (NASDAQ: IPX) submitted a Form 6-K on June 27, 2025. The filing is procedural and contains no operating or financial results. Two exhibits are listed:

  • Exhibit 99.1 – Notice of General Meeting
  • Exhibit 99.2 – Results of Meeting
The document simply records that the company has circulated the notice and subsequently reported the voting outcomes. There are no balance-sheet figures, earnings data, material transactions, or strategic updates. The form was signed by Chief Financial Officer Marcela Castro. Investors should view this as routine corporate housekeeping with negligible immediate impact on valuation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

How many Iperionx (IPX) SEC filings are available on StockTitan?

StockTitan tracks 49 SEC filings for Iperionx (IPX), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Iperionx (IPX)?

The most recent SEC filing for Iperionx (IPX) was filed on October 23, 2025.